Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment

Stock Track11-10

Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology company revealed promising data from its SOLSTICE trial, evaluating the combination of tobevibart and elebsiran.

According to results presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine, 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus (HDV) RNA at Week 48. The treatment was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported.

Investors responded positively to this news, as it represents a significant step forward in addressing an unmet medical need. The combination therapy has already received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency. Vir Biotechnology is now conducting the ECLIPSE registrational program for the combination therapy, with topline data expected in the first quarter of 2027. This progress in the company's pipeline appears to be driving the stock's impressive performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184089781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184089781","market":"sg","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment","media":"Stock Track","content":"<p>Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology company revealed promising data from its SOLSTICE trial, evaluating the combination of tobevibart and elebsiran.</p>\n\n<p>According to results presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine, 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus (HDV) RNA at Week 48. The treatment was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported.</p>\n\n<p>Investors responded positively to this news, as it represents a significant step forward in addressing an unmet medical need. The combination therapy has already received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency. Vir Biotechnology is now conducting the ECLIPSE registrational program for the combination therapy, with topline data expected in the first quarter of 2027. This progress in the company's pipeline appears to be driving the stock's impressive performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology company revealed promising data from its SOLSTICE trial, evaluating the combination of tobevibart and elebsiran.</p>\n\n<p>According to results presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine, 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus (HDV) RNA at Week 48. The treatment was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported.</p>\n\n<p>Investors responded positively to this news, as it represents a significant step forward in addressing an unmet medical need. The combination therapy has already received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency. Vir Biotechnology is now conducting the ECLIPSE registrational program for the combination therapy, with topline data expected in the first quarter of 2027. This progress in the company's pipeline appears to be driving the stock's impressive performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1184089781","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184089781","pubTimestamp":1762737987,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|Vir Biotechnology飙升8.38%，因治疗德尔塔肝炎2期结果积极","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology company revealed promising data from its SOLSTICE trial, evaluating the combination of tobevibart and elebsiran.\nAccording to results presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine, 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus (HDV) RNA at Week 48. The treatment was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported.\nInvestors responded positively to this news, as it represents a significant step forward in addressing an unmet medical need. The combination therapy has already received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency. Vir Biotechnology is now conducting the ECLIPSE registrational program for the combination therapy, with topline data expected in the first quarter of 2027. This progress in the company's pipeline appears to be driving the stock's impressive performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184089781","isCrawlerRequest":true}